sinopharm(01099) continued to climb, rising about 8% in early trading, reaching a new high since late October last year. A few days ago, institutional shareholder BlackRock increased its holdings once again, and since the second half of the year, its accumulated position has increased by nearly 2 percentage points. Credit Suisse stressed that the company will continue to show steady growth in the fourth quarter, and overall annual revenue is expected to reach high single digits. As of press time, Sinopharm was up 8.28% to HK$20.40, with revenue of HK$116 million.
BlackRock increased its holdings by nearly 16 million Sinopharm H shares on Nov. 30, according to the latest stock exchange data. This is also the second increase in its holdings since the second half of the year. From 6.11% to 7.84%. Earlier, Credit Suisse stressed that Sinopharm will continue to show steady growth in the fourth quarter, and overall annual revenue is expected to reach high single digits. CICC said that as the epidemic situation gradually improves and more efforts are made to invest in online retail and new businesses, the company’s future gross profit margin is expected to remain relatively stable.
Massive information, accurate interpretation, all in the Sina Finance APP
